1 Prenatal ochratoxin A exposure, birth outcomes and infant growth in rural Burkina Faso: a human

2 biomonitoring sub-study from the MISAME-III trial

- 3 Authors:
- 4 Yuri Bastos-Moreira,^{1,2} Alemayehu Argaw,² Trenton Dailey-Chwalibóg,² Jasmin El-Hafi,^{1,3} Lionel Olivier
- 5 Ouédraogo,^{2,4} Laeticia Celine Toe,^{2,5} Sarah De Saeger, ^{1,6} Carl Lachat,² and Marthe De Boevre¹

6 **Affiliations:**

- 7 ¹ Center of Excellence in Mycotoxicology and Public Health, MYTOX-SOUTH[®] Coordination Unit, Faculty of
- 8 Pharmaceutical Sciences, Ghent University, Ghent, Belgium
- 9 ² Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University,
- 10 Ghent, Belgium
- 11 ³ Institute of Food Chemistry, University of Münster, Münster, Germany
- 12 ⁴Laboratoire de Biologie Clinique, Centre Muraz, Bobo-Dioulasso, Burkina Faso
- 13 ⁵ Unité Nutrition et Maladies Métaboliques, Institut de Recherche en Sciences de la Santé (IRSS), Bobo-
- 14 Dioulasso, Burkina Faso
- 15 ⁶ Department of Biotechnology and Food Technology, Faculty of Science, University of Johannesburg,
- 16 Doornfontein Campus, Gauteng, South Africa

17 **Corresponding author**

- 18 Marthe De Boevre; Ottergemsesteenweg 460, 9000 Ghent, Belgium;
- 19 Marthe.DeBoevre@UGent.be

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1

- 20 Abbreviations: AFs, aflatoxins; AFG1, aflatoxin G1; AFM1, aflatoxin M1; AIC, Akaike Information Criterion; 21 BEP, balanced energy-protein; BIC, Bayesian Information Criterion; BioSpé, Biospecimen; CPA, cyclopiazonic 22 acid; DON, deoxynivalenol; FBs, fumonisins; FB1, fumonisin B1; GA, gestational age; IARC, International 23 Agency for Research on Cancer; IFA, iron-folic acid; LAZ, length-for-age z-score; LBW, low birth weight; 24 LMICs, low-and-middle income countries; LOD, limit of detection; LLOQ; lower limit of quantification; MISAME, MIcronutriments pour la SAnté de la Mère et de l'Enfant; MUAC, mid-upper arm circumference; OTA, 25 26 ochratoxin A; PTB, preterm birth; RSDr, Repeatability; RSDR, reproducibility; SGA, small-for-gestational age; 27 UPLC-MS/MS, ultra-performance liquid chromatography-tandem mass spectrometry; VAMS, volumetric
- 28 absorptive microsampling; WAZ, weight-for-age z score; WLZ, weight-for-length z score.

29 Abstract

30 Mycotoxin exposure during pregnancy has been associated with adverse birth outcomes and poor infant growth 31 in low- and middle-income countries. We assessed multiple biomarkers and metabolites of exposure to 32 mycotoxins during pregnancy and their associations with birth outcomes and infant growth in 305 pregnant 33 participants, between 30 and 34 completed weeks of gestation, in rural Burkina Faso. In this study, whole blood 34 microsamples were analyzed for mycotoxin concentrations using ultra-performance liquid chromatography 35 coupled to tandem mass spectrometry. Unadjusted and adjusted associations between mycotoxin exposure, and 36 birth outcomes and infant growth at 6 months were estimated using linear regression models for continuous 37 outcomes and linear probability models with robust variance estimation for binary outcomes. Infant growth 38 trajectories from birth to 6 months were compared by exposure status using mixed-effects models with random 39 intercept for the individual infant and random slope for the infant's age. Ochratoxin A (OTA) exposure was 40 detected in 50.8% of the study participants, with aflatoxin G1, aflatoxin M1, cyclopiazonic acid, deoxynivalenol 41 and T-2-toxin being detected in the range of 0.33% and 2.31% of the population. We found no statistically 42 significant (all $p \ge 0.05$) associations between OTA exposure, and birth outcomes and infant growth. Despite 43 this, the findings indicate a significant presence of ochratoxin A among pregnant participants. Public health 44 policies and nutrition-sensitive interventions must ensure that OTA exposure is reduced in Burkina Faso.

45 Keywords: birth outcomes, exposomics, growth, low- and middle-income countries, MISAME-III, mycotoxins,

46 ochratoxin A

47 Background

- 48 Mycotoxins are secondary metabolites from fungi that grow on crops preharvest, as well as in postharvest,
- 49 storage and/or in food processing (Andrews-Trevino et al., 2022; De Boevre et al., 2012; Marin et al., 2013; Pitt
- 50 et al., 2000). Mycotoxin contamination commonly affects popular food items in West Africa, including chilies,
- 51 maize, peanuts, and spices (Abiala et al., 2011; Ngum et al., 2022). The climate conditions of these countries,
- 52 where there is an elevated temperature and humidity level, are favorable for their production (Aasa et al., 2022;
- 53 Compaore et al., 2021). In low- and middle-income countries (LMICs), pregnancies frequently result in adverse
- 54 outcomes such as low birth weight (LBW), preterm birth (PTB), and/or small-for-gestational age (SGA) (Lee et
- al., 2013). While the causes of these outcomes are multifaceted, maternal nutrition significantly impacts both
- 56 pregnancy development and newborn well-being (Ota et al., 2014).

57 According to the International Agency for Research on Cancer (IARC), aflatoxin B1 (AFB1) is classified as 58 carcinogenic to humans (Group 1), while fumonisin B1 (FB1) and ochratoxin A (OTA) are considered possible 59 human carcinogens (Group 2B). Deoxynivalenol (DON) is placed in Group 3, indicating that it has not been 60 classified regarding its carcinogenicity due to insufficient data (IARC (International Agency for Research on 61 Cancer), 1993). It has been suggested that aflatoxins (AFs) and DON hinders protein synthesis resulting in a 62 modified intestinal structure, while fumonisins (FBs) reduce complex sphingolipids. Formerly, a high AFs 63 exposure in newborns has resulted in stunting and/or underweight, while those with a high FBs exposure were also 64 shorter and lighter (Lombard, 2014). In addition, research has also shown that DON can cross the placental barrier 65 in humans (Nielsen et al., 2011; Tan et al., 2023), and is consequently associated with decreased birth weight 66 (Coronel et al., 2010).

67 OTA has a half-life of 35.6 days and is reported to have toxic effects in humans including carcinogenicity, 68 immunotoxicity and nephrotoxicity (Coronel et al., 2010). OTA serves as an effective biomarker of exposure 69 owing to its persistence in blood, as it swiftly binds to plasma proteins with high affinity (Coronel et al., 2010). 70 Previous studies have also revealed transplacental transfer of mycotoxins such as OTA to the fetus in humans 71 (Woo et al., 2012). This exposure during the critical first 1,000 days of life (Groopman et al., 2014) might 72 contribute to suboptimal fetal and infant outcomes (Etzel & Zilber, 2014). Nevertheless, the evidence for the 73 association between mycotoxin exposure during pregnancy and newborn and infant growth outcomes remains 74 inconsistent and are mainly limited with AFs and FBs. While certain studies have documented an association

between exposure to certain mycotoxin groups and a higher risk of adverse birth outcomes and suboptimal infant
growth, others have indicated no clear association or have even suggested a positive correlation with improved
growth (Gönenç et al., 2020; Kyei et al., 2020; Tesfamariam et al., 2020).

78 The presence of mycotoxins in sub-Saharan populations is mainly due to monotonous diets based on contaminated 79 staple food crops (Bankole & Adebanjo, 2003). In Burkina Faso, cereals are consumed in large quantities and have 80 a social, economic, and nutritional significance. Maize is the second most cereal produced, with production 81 reaching 1,710,898 tons in 2019 (Somda et al., 2023). However, in Burkina Faso, the availability of biological and 82 toxicological data on food contamination remains limited (Kpoda et al., 2022), and the implementation of 83 legislation and regulations concerning mycotoxins is lacking (FAO, 2003; Warth et al., 2012). Using data from 84 the Biospecimen (BioSpé) sub-study of the MISAME-III (MIcronutriments pour la SAnté de la Mère et de 85 l'Enfant) trial in rural Burkina Faso, we aimed to quantify maternal mycotoxin exposure during pregnancy and 86 investigated the association with birth outcomes and infant growth.

87 Methods

88 Study setting, participants, and design

89 Study protocols for the main MISAME-III trial (Vanslambrouck et al., 2021) and the BioSpé sub-study nested

90 under the MISAME-III trial (Bastos-Moreira et al., 2023) were published previously. The research took place

91 within the catchment areas of six rural health centers located in the Houndé district of Burkina Faso. These areas

92 have a Sudano-Sahelian climate, marked by a dry season lasting from September/October to April, with farming

93 serving as the primary source of income.

94 The objective of the BioSpé research was to examine the impact of a multi-micronutrient enriched BEP

95 supplement on pregnant individuals and their infants, aiming to assess the physiological effects of the

96 supplementation on maternal health, infant birth and growth outcomes. This evaluation was conducted through

97 comprehensive multi-omics analyses, human biomonitoring of contaminants and assessment of biological aging

98 markers (Bastos-Moreira et al., 2023; Hanley-Cook et al., 2023). In the present study, we report the associations

99 between maternal exposure to mycotoxins during pregnancy and various growth and nutritional status outcomes

100 at birth and during infancy.

101 Exposure and outcomes

- 102 The present study considered exposure to a range of mycotoxins listed in Table 2. However, aflatoxin B1
- 103 (AFB1)-lysine exposure was not assessed due to the current unavailability of the commercial analytical standard
- 104 for this specific mycotoxin. Mycotoxin exposure was determined as the presence of a concentration equal to or
- 105 greater than the limit of detection (LOD) in whole blood microsamples.
- 106 The outcomes of interest were birth outcomes, such as birth weight, SGA, LBW, gestational age (GA), PTB,
- 107 length, mid-upper arm circumference (MUAC), head circumference, ponderal index, chest circumference, and
- 108 infant growth and nutritional status at the age of 6 months, such as LAZ, weight-for-age (WAZ) and weight-for-
- 109 length z-score (WLZ), MUAC, head circumference, hemoglobin, stunting, underweight wasting and anemia. We
- 110 additionally assessed the associations between mycotoxin exposure and infant growth trajectories (height,
- 111 weight, upper-arm and head circumferences) during the first 6 months postpartum.
- 112 PTB was characterized as the delivery of a newborn before completing 37 weeks of gestation. SGA was defined
- as a newborn weight less than the 10th percentile of weight for the same GA and sex, as per the International
- 114 Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st) (Villar et al., 2014).
- 115 Anthropometric z-scores of LAZ, WAZ and WLZ were calculated based on the WHO Child Growth Standards
- 116 with stunting, underweight and wasting defined as LAZ, WAZ and WLZ values below 2 SD from the median
- value for same age and sex from the reference population (de Onis & Branca, 2016). Newborn Rohrer's ponderal
- 118 index was calculated as weight in g divided for length in cm cubed (i.e., weight/length³ (g/cm³) \times 1,000).

119 Data collection

- 120 The MISAME-III trial data were collected through computer-assisted personal interviewing using
- 121 SurveySolutions (version 21.5) on tablets and then transferred to a central server at Ghent University.
- 122 Sociodemographic and other relevant characteristics of participants and study households were collected at
- 123 baseline during the first and third trimester of pregnancy. All newborn anthropometry measurements were taken
- 124 within 12 hours of birth, whereas mothers were invited for follow-up growth assessment every month until 6
- 125 months of age. Measurements were conducted in duplicates, with a third measurement taken if a significant
- 126 discrepancy was observed between the duplicate measurements. Length was assessed using a Seca 416
- 127 Infantometer, measuring to the nearest 1 mm, while weight was measured with a Seca 384 scale, accurate to the

128 nearest 10 g. Head circumference, thoracic circumference, and MUAC were measured to the nearest 1 mm using

- 129 a Seca 212 measuring tape. GA was determined utilizing a portable ultrasound (SonoSite M-Turbo, FUJIFILM
- 130 SonoSite, Bothell, Washington, USA) during the first and early stages of the second trimester of pregnancy.
- 131 Biospecimen collection through volumetric absorptive microsampling
- 132 The samples collection procedure was described in detail previously (Bastos-Moreira et al., 2023). Pregnant
- 133 participants (n=305) were invited to their local health center at 30-34 weeks of gestation, between March and
- 134 July 2021. Since volumetric absorptive microsampling (VAMS) collection for the different analyses in the study
- 135 were conducted in the same visit, to preserve metabolites for metabolomics, participants were advised to fast on
- 136 the morning of VAMS collection. A total amount of 40 μ L (2 × 20 μ L VAMS tips) of capillary whole blood was
- 137 collected by capillary sampling onto a VAMS tip, namely MitraTM, via direct finger incision for mycotoxins
- 138 analysis.
- 139 Then, 20 µL Mitra Clamshells were transported from the health centers to the Institut de Recherche en Sciences
- 140 de la Santé in Bobo-Dioulasso, Burkina Faso for shipment at room temperature to Ghent University, Belgium.
- 141 For storage at -80°C until analysis, VAMS were placed in Mitra Autoracks inside a storage bag containing
- 142 desiccant bags.
- 143 Items used for VAMS collection were purchased from Neoteryx (Torrance, CA, USA).

144 Sample extraction procedure

145 **Preparation of calibration curve**

146 For the method development, ethylenediaminetetraacetic acid anticoagulated blood were supplied by Red Cross 147 Flanders (Ghent, Belgium) and kept at -80 °C until use. These blood samples were pipetted in 2 mL Eppendorf 148 tubes and fortified (spiked) with a mix of 35 mycotoxins at five different concentration levels. Then, each 149 calibration curve point was prepared by dipping a VAMS tip into the designated pool of spiked whole blood 150 concentration. After the tip was fully colored, contact with the whole blood was maintained for 7 seconds to 151 obtain full absorption. Overfilling of the VAMS devices was avoided by not completely immersing the tip into 152 the whole blood, as described previously (Vidal et al., 2021). The devices were subsequently dried in their 153 accompanying MitraTM clamshells for \geq 3 hours at room temperature.

154 Mycotoxins extractions from VAMS

- 155 A VAMS multi-mycotoxin extraction methodology was previously established in our laboratory (Vidal et al.,
- 156 2021). Briefly, extraction began by transferring the VAMS tips from the plastic handles into 2 mL Eppendorf
- 157 tubes, and pipetting 250 μ L extraction solvent (acetonitrile/water/acetic acid, 59/40/1, v/v/v), containing the
- 158 internal standards 0.125 μ g/L ¹³C₁₇–AFB1 and 0.25 μ g/L for ¹³C₁₅ deoxynivalenol (DON), ¹³C₃₄–FB1 and
- 159 $0.125 \,\mu$ g/L for ¹³C₁₈-zearalenone, to the sample tubes. Subsequently, samples were ultrasonicated for 30 minutes
- 160 and shaken for 60 minutes at 25°C with rotation at 1,400 rpm in a Biosan TS-100 Thermo-Shaker followed by
- 161 centrifugation (10 minutes at 10,000g, room temperature). The tips were discarded, and the supernatant was
- 162 pipetted to an 8 mL glass tube and evaporated under nitrogen on a Turbovap LV Evaporator (Biotage, Charlotte,
- 163 USA).
- 164 Afterwards, the extracts were reconstituted in 50 μ L of injection solvent (methanol/water, 60/40, v/v), vortexed,
- 165 centrifuged (for 10 min at 5000 g) and filtered (22 μm, PVDF, Durapore[®], Cork, Ireland). Lastly, samples were
- 166 transferred into vials before 10 μL were injected into the ultra-performance liquid chromatography coupled to
- 167 tandem mass spectrometry (UPLC -MS/MS) instrument.

168 UPLC-MS/MS analysis

- 169 Sample analysis was conducted using a Waters UPLC[®] system coupled to a Quattro XEVO TQ-XS mass
- 170 spectrometer (Waters, Manchester, UK). Detailed instrument parameters can be found in a previous study (Vidal
- 171 et al., 2021). Data acquisition and processing were carried out using MassLynx[™] version 4.1 and QuanLynx[®]
- 172 version 4.1 software (Waters, Manchester, UK).

173 Validation of the VAMS-based UPLC-MS/MS method

- 174 The UPLC-MS/MS method validation experiment was conducted in three independent replicates over 4 different
- 175 days. The method validation was re-validated from a previous method (Vidal et al., 2021) to optimize the
- 176 extraction protocol and mass spectrometry parameters prior to analysis of BioSpé samples. The method was
- 177 validated following the guidelines of the European Commission (EC) decision No. 2002/657 (European
- 178 Commission, 2002) and Commission Regulation (EU) No. 401/2006 (European Commission, 2006).

179 Whole blood samples supplied by Red Cross Flanders were spiked at five different concentration levels to 180 determine the limit of detection (LOD) and lower limit of quantification (LLOQ). LLOQ is the concentration at 181 which the analytical method cannot operate with acceptable precision (Currie, 1995; Thompson et al., 2002). 182 Apparent recoveries were attained by comparing the detected concentrations (calculated using the analyzed 183 calibration curve in pure solvent) against the spiked concentrations. The mean and standard deviation of the 184 detected concentrations were calculated for each concentration level. The intraday precision (repeatability 185 (RSDr)) and interday precision intra-laboratory (reproducibility (RSDR) of the method were expressed as the 186 variation coefficient (CV %).

187 Statistical analysis

188 Data cleaning and statistical analyses were conducted using Stata (Stata Statistical Software: release 17;

189 StataCorp), with statistical significance evaluated at a two-sided significance level of p < 0.05. Descriptive

190 statistics are presented using means \pm SD or medians (range) for the continuous variables, depending on the

191 nature of the data distribution, and frequencies (percentages) for nominal variables.

192 In the study sample, only exposure to OTA was found in an adequate number of participants to assess the 193 association with newborn and infant outcomes. We assessed the association between OTA exposure and the 194 study outcomes at birth and 6 months of age and employed linear regression models to analyze continuous 195 outcomes and linear probability models with robust variance estimation for binary outcomes. All models were 196 adjusted for clustering by the health center catchment areas and allocation for the prenatal and postnatal BEP 197 interventions. Furthermore, adjusted models additionally included the covariates maternal age, primiparity, 198 baseline BMI and hemoglobin concentration, and household size, wealth index score, access to improved water 199 and sanitation, and food security status.

We also compared OTA exposed and non-exposed groups by growth trajectories from birth to 6 months. For this purpose, We employed mixed-effects regression models with a random intercept for each individual infant and a random slope for the infant's age in months. We investigated the optimal growth trajectory that aligns with our data by visually examining graphs and comparing model fit indices, such as AIC (Akaike Information Criterion) and BIC (Bayesian Information Criterion) values. As a result, we utilized quadratic models for height, weight, and MUAC, along with a restricted cubic spline model with 4 knots for head circumference. We accounted for the correlation among repeated measurements within an individual by considering an unstructured covariance

- 207 matrix. Fixed effects in the model included the main effect of exposure status, age, and exposure by age
- 208 interaction, estimating the difference in monthly changes in the outcome between exposure and unexposed
- 209 groups. Models were further adjusted for the aforementioned covariates.
- 210 Results
- 211 Participants characteristics
- 212 Of the 305 study participants, birth outcomes and infant growth at 6 months were assessed on 296 and 274
- participants, respectively (Figure 1). Mean \pm SD age of the study participants was 24.1 \pm 5.61 years and 45.6%
- of the mothers had at least a primary education (**Table 1**). The mean ± SD maternal BMI at study inclusion was
- 215 22.0 \pm 3.17 kg/m² with 7.77% underweight (BMI<18.5 kg/m²). More than two-thirds (70.1%) of the mothers
- 216 were from food insecure households, 32.1% were anemic, and the mean \pm SD maternal dietary diversity score
- during pregnancy was 4.05 ± 1.29 food groups.
- 218 Mycotoxins exposure and newborn and infant growth and nutritional status
- 219 The microsample (VAMS sample) whole blood analysis using the ultra-performance liquid-performance
- 220 chromatography-mass spectrometry analysis showed that, aside from OTA, almost all participants were found to
- be not exposed to most mycotoxins (**Table 2**). OTA exposure was detected in 50.8% of the study participants
- 222 with a median (range) concentration of 0.01 (<LOD, 8.21) µg/L. Other mycotoxins including aflatoxin G
- 223 (AFG1), aflatoxin M1 (AFM1), cyclopiazonic acid (CPA), DON and T-2-toxin were detected in the range of
- 2.31% and 0.33% of the population. For the remaining mycotoxins, no exposure was detected through wholeblood analysis.

There were no statistically significant associations between maternal OTA exposure during pregnancy and the duration of gestation or size at birth (**Table 3**). Similarly, OTA exposure was not significantly associated with the aforementioned infant growth and nutritional status at the age of 6 months (**Table 4**). We also found no significant association between OTA exposure and growth trajectories from birth to the age of 6 months (**Figure** 2).

231 Validity of the UPLC-MS/MS

- 232 The described UPLC-MS/MS conditions were sufficient for OTA determination (Figure 3). Calibration curves
- 233 were established with correlation coefficient >0.95. The LODs of the various mycotoxins
- 234 metabolites/biomarkers ranged in the low µg/L level from 0.05 (AFG1), 0.11 (AFM1), 1.44 (CPA), 0.40 (DON),
- 235 0,09 (OTA), to 0.59 µg/L (T-2-toxin). The LLOQs were 0.09 (AFG1), 0.20 (AFM1), 2.65 (CPA), 0,80 (DON),
- 236 0.17 (OTA), to 1.10 (T-2 Toxin). Satisfactory apparent recoveries were achieved for all detected mycotoxins
- with the mean values of 89% -105%. The acceptable RSDr and RSDR for the different mycotoxins and
- 238 metabolites was <15.

239 Discussion

- 240 The present study found a high prevalence of OTA exposure (50.8%) during pregnancy. Exposures to
- 241 mycotoxins, such as AFG1, AFM1, CPA, DON and T-2-toxin, were detected in relatively fewer subjects,
- 242 whereas other mycotoxins were not detected. We found no apparent association between maternal OTA
- exposure during pregnancy and newborn anthropometry, and infant growth and nutritional status.

244 OTA is mainly produced by select species of Aspergillus, Monascus, and Penicillium, and is often found 245 contaminating food sources (Alshannaq & Yu, 2017; Frisvad et al., 2005). As a result, avoiding dietary exposure 246 to OTA is challenging due to the widespread occurrence of these toxins in various food stuffs (Pfohl-Leszkowicz 247 & Manderville, 2007). In Burkina Faso, Ware et al. (2017) noted OTA contamination in 7.5% of infant formulas 248 derived from maize. The highest concentration recorded was in a sample containing a mixture of maize, beans, 249 peanuts and soya (3.2 mg/kg). In the papers reviewed by Arce-López et al. (2020), OTA was of the most 250 frequently detected mycotoxins in blood, plasma and serum samples (Arce-López et al., 2020). Authors reported 251 incidence levels of 64.9% (Ali et al., 2018; Fan et al., 2019; Karima et al., 2010; Tesfamariam et al., 2022), and 252 concluded that the global population is generally exposed to OTA due to its long half-life in these matrices 253 (Arce-López et al., 2020). In addition, the occurrence of OTA detected in the present study is comparable to 254 previous literature. Fan et al. (2019) analyzed multi-mycotoxin exposure in plasma samples of 260 adults in 255 China and detected OTA as the most abundant mycotoxin detected in 27.7% of the participants (range: 0.31-9.18 256 µg/L) (Fan et al., 2019), and in another study the OTA prevalence was 28% of 107 serum samples from Tunisia 257 (range: 0.12 and 11.67 µg/L) (Karima et al., 2010). Likewise, in plasma samples from Bangladesh, OTA 258 concentrations were between 0.10 and 0.87 μ g/L (mean 0.35 \pm 0.20 μ g/L) in women, while for males, the values

were $0.16-3.07 \ \mu g/L$ (mean $0.70 \pm 0.71 \ \mu g/L$) (Ali et al., 2018). The detection and quantification limits for these studies were 0.04 and 0.10 $\mu g/L$, 0.10 and 0.20 $\mu g/L$ and 0.05 and 0.10 $\mu g/L$ respectively (Ali et al., 2018; Fan et al., 2019; Karima et al., 2010).

262 On the other hand, exposure to mycotoxins other than OTA was found to be low in the study population as 263 compared to what has been reported previously in LMICs (Abdulrazzaq et al., 2002; Lauer et al., 2020; Mahdavi 264 et al., 2010; Tesfamariam et al., 2022). The variations in physicochemical properties of mycotoxins lead to 265 differences in their toxicokinetic profiles. This results in a wide range of excretion amounts and times, spanning 266 from hours to days, and from parts per billion to parts per trillion concentrations. It is conceivable that the used 267 UPLC-MS/MS system may not detect the lowest concentrations of mycotoxin metabolites. Additionally, 268 participants were instructed to fast on the morning of VAMS collection, since Mitra tips were used for both 269 metabolomics and mycotoxin analysis simultaneously. This fasting period may have accelerated the metabolism 270 of certain mycotoxins, hence it is imperative to investigate the stability of mycotoxins during food processing, 271 their behavior within the digestive system, and conduct toxicodynamic and toxicokinetic studies (McCormick et 272 al., 2015). Additionally, understanding the formation process of these metabolites, along with comprehension of 273 their structure and molecular mass, is the key to resolving the analytical and technological hurdles associated 274 with them. Therefore, given these facts, there may be underreporting of exposure to certain mycotoxins due to 275 their short-half lives.

276 No statistically significant associations were found between OTA exposure and birth outcomes, including 277 gestational duration or birth size. Similarly, OTA exposure was not significantly associated with infant growth 278 and nutritional status. OTA exposure has been previously reported to be unassociated to anthropometric data 279 (Akdemir et al., 2010; Erdal & Yalçın, 2022; Jonsyn-Ellis, 2000; Silva et al., 2020) other than body weight 280 (Skaug et al., 2001). On the other hand, an association between poor birth outcomes and infant growth and 281 exposure to other mycotoxin groups have been reported inconsistently. For instance, a study conducted in 282 Ethiopia discovered an association between chronic maternal exposure to AF and decreased fetal growth 283 trajectories, as determined by fetal biometry derived from ultrasound estimates. However, the same study did not 284 report an association of AF exposure with birth anthropometry (Tesfamariam et al., 2022). Yousef et al. (2002) 285 also did not find any significant correlation between AFM1 exposure and GA, postnatal age, clinical condition or 286 gender in the United Arab Emirates. A systematic review of studies that evaluated mycotoxin exposure and 287 infant growth also found inconsistent results (Tesfamariam et al., 2020). With the variation in the detected types

and concentrations of mycotoxins and confounding factors adjusted in previous literature, It's understandablethat only certain studies found.

Despite the lack of apparent association between OTA exposure and newborn and infant anthropometry in the present study, the high prevalence of OTA exposure can potentially have severe adverse consequences. After its absorption from the gastrointestinal tract, OTA binds mainly to albumin with high affinity, resulting in its long half-life (Kőszegi & Poór, 2016). Based on previous studies, The OTA mechanism is understood to be carcinogenic, hepatotoxic, immunotoxic, neurotoxic and teratogenic (el Khoury & Atoui, 2010; Ringot et al., 2006). In humans, OTA exposure has been associated with adverse health effects such as Tunisian Nephropathy (Hassen et al., 2004), esophageal and gastric tumors (Cui et al., 2010; Liu et al., 2015), as well as testicular

cancer (Schwartz, 2002).

298 Given the risks associated with mycotoxins exposure in both the current population and similar demographics,

299 Matumba *et al.* (2021) put forward an extensive strategy for the prevention and management of mycotoxin

300 contamination in grains, specifically tailored for LMICs This framework comprises five key recommendations,

301 which include: i) Enhancing the strength and health of plants; ii) Decreasing the population of toxigenic fungi

302 during plant growth and storage; iii) Swiftly reducing the moisture content of grains and avoiding rehydration;

303 iv) Protecting the outer structure of seeds/grains; and v) Thoroughly cleaning and removing components at high

304 risk of mycotoxin contamination. (Matumba et al., 2021).

305 The internal method validation showed a good performance of mycotoxin detection as suggested by parameters 306 including the LOD, LLOO, apparent recovery, RSDr and RSDR parameters. These findings are also supported 307 by a previous validation conducted in the same lab (Vidal et al., 2021). To our understanding, this marks the first 308 use of VAMS for mycotoxin analysis in the whole blood of pregnant women within a LMIC setting. Considering 309 the benefits provided by VAMS and the resilient method established previously, VAMS sampling can serve as 310 an alternative method to venous sampling for conducting quantitative screening of mycotoxin exposure (Vidal et 311 al., 2021). In addition, considering the toxicokinetic profiles of the detected mycotoxins, this microsampling 312 technique will additionally emphasize the impact of mycotoxin exposure on human health, facilitating 313 associations to be interpreted with adverse health effects.

314 Strengths and limitations

315 Some of the strengths of the present study are the timely and robust assessment of study outcomes including 316 determination of GA using ultrasonography and the assessment of birth outcomes within 12 hours of birth. 317 Despite the prospective design of the study, mycotoxin exposure was determined during the third trimester of 318 pregnancy leading to a narrow time gap between exposure and outcomes assessment. Direct determination of 319 mycotoxin exposure using biomarkers is superior to the assessment in foodstuffs used in other studies (De 320 Boevre et al., 2013). The VAMS procedure used for sampling in the present study facilitated sample collection, 321 wherein a delicate finger or heel incision (for infants less than 10 kilos) is required without participants travelling 322 long distances to clinical services, and in addition, the small sample volumes collected is favorable for anemic 323 participants and newborns. VAMS provided additional advantages concerning sample handling, storage, and 324 transportation. The procedure has also been shown to be robust and valid for assessing mycotoxin exposure 325 (Vidal et al., 2021) since the UPLC-MS/MS analytical method was previously reported to be highly sensitive 326 and specific (Tesfamariam et al., 2022). However, only a limited number of biomarkers have undergone 327 validation for assessing mycotoxin exposure, specifically AFM1, AFB1-N7-guanine, and DON-glucuronides in 328 urine, as well as the adduct of AFB1 with albumin and AFB1-lysine in human plasma (Vidal et al., 2018). In our 329 study, exposure to AFB1-lysine was not assessed due to the current unavailability of the commercial standard, 330 for this reason only the free mycotoxins AFB1, AFB2 AFG1 AFG2 and AFM1 were measured. Therefore, 331 results obtained using non-validated biomarkers (such as whole blood OTA) should be approached with caution. 332 Furthermore, there are alternative matrices to blood which offer interesting advantages. Even though present at a 333 lower concentration in urine than in blood, OTA in urine was demonstrated in some studies to be a better 334 indicator of exposure to OTA (Castegnaro et al., 2006; Gilbert et al., 2001; Pfohl-Leszkowicz A et al., 2006). In 335 a study employing both serum and urinary biomarkers of OTA exposure, a more robust correlation was observed 336 between dietary OTA intake and urinary OTA levels compared to serum OTA levels (Gilbert et al., 2001). 337 Lastly, mycotoxin exposure data from only a single time point during pregnancy was considered. Future studies, 338 using repeated mycotoxins measurements, will provide an insight into the effects of mycotoxins and their 339 physicochemical properties in relation to the timing of exposure.

340 Conclusion

- 341 Although the present study did not yield any evidence of associations between OTA and birth outcomes or infant
- 342 growth, we found evidence for a significant presence of OTA exposure among pregnant participants. Public
- 343 health policies and nutrition-sensitive interventions need to prioritize the reduction of mycotoxin exposure in
- 344 rural Burkina Faso.

345 Data availability request

- 346 Due to the sensitive nature of the data, access to the data will be facilitated through a data-sharing agreement.
- 347 For inquiries, please reach out to carl.lachat@ugent.be and marthe.deboevre@ugent.be. Additionally, supporting
- 348 study documents such as the study protocol and questionnaires can be accessed publicly on the study's website:
- 349 https://misame3.ugent.be (accessed on 07 December 2023).

350 Statements and Declarations

351 Funding

- 352 The main trial work of MISAME-III received support from the Bill & Melinda Gates Foundation
- 353 (OPP1175213). The mycotoxins sampling and analysis was supported by Fonds Wetenschappelijk Onderzoek
- 354 (project No G085921N). MDB received support from the European Research Council through the European
- Union's Horizon 2020 research and innovation program (grant agreement No 946192, HUMYCO). The funders
- did not participate in the study's design and execution, data collection, management, analysis, or interpretation,
- 357 nor were they involved in the preparation, review, or approval of the manuscript.

358 Conflicts of interest

359 The authors have no relevant financial or non-financial interests to disclose.

360 Author contributions

- 361 Author Contributions: Author Conceptualization: Y.B.-M., A.A., T.D.-C., S.D.S., CL and M.D.B.;
- 362 Methodology: Y.B-M., J-E-H., S.D.S. and M.D.B.; Software: Y.B.-M., A.A., and T.D.-C.; Validation: Y.B-M.,
- 363 J-E-H. and M.D.B.; Formal analysis: Y.B-M and A.A.; Investigation: Y.B.-M., T.D.-C, J.E-H., L.O. and
- 364 M.D.B.; Resources: Y.B.-M., T.D.-C., L.O., L.C.T., S.D.S, C.L. and M.D.B.; Data Curation: Y.B.-M., A.A.,
- 365 T.D.-C. and L.O.; Writing—Original Draft: Y.B.-M. and A,A.; Writing—Review and Editing: Y.B.-M., A.A.,
- 366 T.D.-C., J.E-H., L.O., L.C.T., S.D.S., C.L and M.D.B.; Supervision: T.D.-C., S.D.S, C.L., and M.D.B.; Project
- 367 Administration: Y.B.-M., T.D.-C., L.O., C.L., S.D.S. and M.D.B.; Funding Acquisition: T.D.-C., C.L. and
- 368 M.D.B.

369 Ethical considerations

- 370 The study protocol received approval from the Ethical Committee of Ghent University Hospital in Belgium
- 371 (B670201734334) and the Ethical Committee of Institut de Recherche en Sciences de la Santé in Burkina Faso
- 372 (50-2020/CEIRES). All participants provided written informed consent prior to their involvement in the study.

373 Consent to participate

374 All participants in the study provided informed consent.

375 Consent for publication

376 All the authors also agreed on the publication of this article.

377 **References**

Aasa, A. O., Fru, F. F., Adelusi, O. A., Oyeyinka, S. A., & Njobeh, P. B. (2022). A review of toxigenic fungi and
mycotoxins in feeds and food commodities in West Africa. *World Mycotoxin Journal*, 1–16.

380 https://doi.org/10.3920/wmj2021.2766

Abdulrazzaq, Y. M., Osman, N., & Ibrahim, A. (2002). Fetal exposure to aflatoxins in the United Arab Emirates.

382 Annals of Tropical Paediatrics, 22(1), 3–9. https://doi.org/10.1179/027249302125000094

- Abiala MA, Ezekiel CN, Chukwura NI, & Odebode AC. (2011). Toxigenic Aspergillus section Flavi and aflatoxins
 in Dried Yam Chips in Oyo State, Nigeria. *Academia Arena*, 5, 3. http://www.sciencepub.net
- 385 Akdemir, C., Ulker, O. C., Basaran, A., Ozkaya, S., & Karakaya, A. (2010). Estimation of ochratoxin A in some
- 386 Turkish populations: An analysis in urine as a simple, sensitive and reliable biomarker. *Food and Chemical*

387 *Toxicology*, 48(3), 877–882. https://doi.org/10.1016/J.FCT.2009.12.026

- Ali, N., Hossain, K., & Degen, G. H. (2018). Blood plasma biomarkers of citrinin and ochratoxin A exposure in
 young adults in Bangladesh. *Mycotoxin Research*, 34(1), 59–67. https://doi.org/10.1007/S12550-017-0299-
- 390 5/TABLES/5
- Alshannaq, A., & Yu, J. H. (2017). Occurrence, Toxicity, and Analysis of Major Mycotoxins in Food.
 International Journal of Environmental Research and Public Health 2017, Vol. 14, Page 632, 14(6), 632.
- 393 https://doi.org/10.3390/IJERPH14060632
- Andrews-Trevino, J., Webb, P., Shrestha, R., Pokharel, A., Acharya, S., Chandyo, R., Davis, D., Baral, K., Wang,
- J.-S., Xue, K., & Ghosh, S. (2022). Exposure to multiple mycotoxins, environmental enteric dysfunction and
- 396 child growth: Results from the AflaCohort Study in Banke, Nepal. *Maternal & Child Nutrition*, e13315.

397 https://doi.org/10.1111/MCN.13315

- 398 Arce-López, B., Lizarraga, E., Vettorazzi, A., & González-Peñas, E. (2020). Human Biomonitoring of Mycotoxins 399 in Blood, Plasma and Serum in Recent Years: A Review. Toxins, 12(3). 400 https://doi.org/10.3390/TOXINS12030147
- Bankole, S. A., & Adebanjo, A. (2003). Mycotoxins in food in West Africa: current situation and possibilities of
 controlling it. *African Journal of Biotechnology*, 2(9), 254–263. http://www.academicjournals.org/AJB
- 403 Bastos-Moreira, Y., Ouédraogo, L., De Boevre, M., Argaw, A., de Kok, B., Hanley-Cook, G. T., Deng, L.,
- 404 Ouédraogo, M., Compaoré, A., Tesfamariam, K., Ganaba, R., Huybregts, L., Toe, L. C., Lachat, C.,
- 405 Kolsteren, P., Saeger, S. De, & Dailey-Chwalibóg, T. (2023). A Multi-Omics and Human Biomonitoring
- 406 Approach to Assessing the Effectiveness of Fortified Balanced Energy–Protein Supplementation on

- 407 Maternal and Newborn Health in Burkina Faso: A Study Protocol. Nutrients 2023, Vol. 15, Page 4056,
- 408 15(18), 4056. https://doi.org/10.3390/NU15184056
- 409 Castegnaro, M., Canadas, D., Vrabcheva, T., Petkova-Bocharova, T., Chernozemsky, I. N., & Pfohl-Leszkowicz,
- 410 A. (2006). Balkan endemic nephropathy: Role of ochratoxins A through biomarkers. *Molecular Nutrition &*
- 411 Food Research, 50(6), 519–529. https://doi.org/10.1002/MNFR.200500182
- 412 Compaore, H., Samandoulougou, S., Ware, L. Y., Bambara, A., Ratongue, H., Sawadogo, I., & Sawadogo-Lingani,
- H. (2021). Identification of Aspergillus section Flavi and Fumigati in maize grown in Burkina Faso. *Int. J. Biosci.* https://doi.org/10.12692/ijb/18.6.25-36
- 415 Coronel, M. B., Sanchis, V., Ramos, A. J., & Marin, S. (2010). Review. Ochratoxin A: presence in human plasma
- 416 and intake estimation. *Food Science and Technology International = Ciencia y Tecnologia de Los Alimentos*
- 417 Internacional, 16(1), 5–18. https://doi.org/10.1177/1082013209353359
- 418 Cui, J., Xing, L., Li, Z., Wu, S., Wang, J., Liu, J., Wang, J., Yan, X., & Zhang, X. (2010). Ochratoxin A induces
- G(2) phase arrest in human gastric epithelium GES-1 cells in vitro. *Toxicology Letters*, *193*(2), 152–158.
 https://doi.org/10.1016/J.TOXLET.2009.12.019
- 421 Currie, L. A. (1995). Nomenclature in evaluation of analytical methods including detection and quantification
 422 capabilities. *Pure and Applied Chemistry*, 67(10), 1699–1723.
 423 https://doi.org/10.1351/PAC199567101699/MACHINEREADABLECITATION/RIS
- 424 De Boevre, M., Di Mavungu, J. D., Landschoot, S., Audenaert, K., Eeckhout, M., Maene, P., Haesaert, G., & De
- 425 Saeger, S. (2012). Natural occurrence of mycotoxins and their masked forms in food and feed products.
 426 *Http://Dx.Doi.Org/10.3920/WMJ2012.1410*, 5(3), 207–219. https://doi.org/10.3920/WMJ2012.1410
- 427 De Boevre, M., Jacxsens, L., Lachat, C., Eeckhout, M., Di Mavungu, J. D., Audenaert, K., Maene, P., Haesaert,
 428 G., Kolsteren, P., De Meulenaer, B., & De Saeger, S. (2013). Human exposure to mycotoxins and their
 429 masked forms through cereal-based foods in Belgium. *Toxicology Letters*, 218(3), 281–292.
 430 https://doi.org/10.1016/J.TOXLET.2013.02.016
- de Onis, M., & Branca, F. (2016). Childhood stunting: a global perspective. *Maternal & Child Nutrition*, *12 Suppl 1*(Suppl 1), 12–26. https://doi.org/10.1111/MCN.12231
- el Khoury, A. E., & Atoui, A. (2010). Ochratoxin A: General Overview and Actual Molecular Status. *Toxins 2010*, *Vol. 2, Pages 461-493*, 2(4), 461–493. https://doi.org/10.3390/TOXINS2040461
- Erdal, İ., & Yalçın, S. S. (2022). The relationship between ochratoxin A and blood pressure in adolescents. *Environmental Toxicology and Pharmacology*, 95, 103959. https://doi.org/10.1016/J.ETAP.2022.103959

- Etzel, R. A., & Zilber, J. J. (2014). Reducing Malnutrition: Time to Consider Potential Links Between Stunting
 and Mycotoxin Exposure? *Pediatrics*, *134*(1), 4–6. https://doi.org/10.1542/PEDS.2014-0827
- 439 European Commission. (2002). Commission Decision of 12 August 2002 implementing Council Directive
- 440 96/23/EC concerning the performance of analytical methods and the interpretation of results (Text with EEA
- 441 *relevance) (notified under document number C(2002) 3044) (OJ L 221 17.08.2002.*
- 442 European Commission. (2006). COMMISSION REGULATION (EC) No 401/2006 of 23 February 2006 laying
- 443 down the methods of sampling and analysis for the official control of the levels of mycotoxins in foodstuffs.
- 444 Fan, K., Xu, J., Jiang, K., Liu, X., Meng, J., Di Mavungu, J. D., Guo, W., Zhang, Z., Jing, J., Li, H., Yao, B., Li,
- 445 H., Zhao, Z., & Han, Z. (2019). Determination of multiple mycotoxins in paired plasma and urine samples
- to assess human exposure in Nanjing, China. *Environmental Pollution*, 248, 865–873.
 https://doi.org/10.1016/J.ENVPOL.2019.02.091
- 448 FAO. (2003). Worldwide regulations for mycotoxins in food and feed in 2003.
 449 https://www.fao.org/3/y5499e/y5499e0d.htm
- 450 Frisvad, J. C., Thrane, U., Samson, R. A., & Pitt, J. I. (2005). Important mycotoxins and the fungi which produce
 451 them. Advances in Experimental Medicine and Biology, 571, 3–31. https://doi.org/10.1007/0-387-28391-
- 452 9_1/COVER
- Gilbert, J., Brereton, P., & MacDonald, S. (2001). Assessment of dietary exposure to ochratoxin A in the UK using
 a duplicate diet approach and analysis of urine and plasma samples. *Food Additives and Contaminants*,

455 *18*(12), 1088–1093. https://doi.org/10.1080/02652030110070030

- Gönenç, İ. M., Yilmaz Sezer, N., & Yilmaz, S. (2020). Mycotoxin exposure and pregnancy. *Critical Reviews in Toxicology*, 50(7), 594–604. https://doi.org/10.1080/10408444.2020.1803791
- 458 Groopman, J. D., Egner, P. A., Schulze, K. J., Wu, L. S. F., Merrill, R., Mehra, S., Shamim, A. A., Ali, H., Shaikh,

459 S., Gernand, A., Khatry, S. K., LeClerq, S. C., West, K. P., & Christian, P. (2014). Aflatoxin exposure during

- the first 1000 days of life in rural South Asia assessed by aflatoxin B1-lysine albumin biomarkers. *Food and*
- 461 *Chemical Toxicology*, 74, 184–189. https://doi.org/10.1016/J.FCT.2014.09.016
- 462 Hanley-Cook, G. T., Bastos-Moreira, Y., Martens, D. S., Dailey-Chwalibóg, T., Toe, L. C., Kok, B. de, Ouédraogo,

463 L., Argaw, A., Tesfamariam, K., Kolsteren, P., Huybregts, L., Nawrot, T. S., Saeger, S. De, Boevre, M. De,

- 464 & Lachat, C. (2023). Prenatal multiple micronutrient-fortified balanced energy-protein supplementation and
- 465 newborn telomere length and mitochondrial DNA content: a randomized controlled efficacy trial in rural
- 466 Burkina Faso. *MedRxiv*, 2023.11.22.23298825. https://doi.org/10.1101/2023.11.22.23298825

- 467 Hassen, W., Abid-Essafi, S., Achour, A., Guezzah, N., Zakhama, A., Ellouz, F., Creppy, E. E., & Bacha, H. (2004).
- 468 Karyomegaly of tubular kidney cells in human chronic interstitial nephropathy in Tunisia: respective role of
- 469 Ochratoxin A and possible genetic predisposition. *Human & Experimental Toxicology*, 23(7), 339–346.
- 470 https://doi.org/10.1191/0960327104HT458OA
- 471 IARC (International Agency for Research on Cancer). (1993). Some naturally occurring substances: heterocyclic
- 472 aromatic amines and mycotoxins. *IARC Monogr Eval Carcinog Risk Chem Hum*, 56(October 1982), 397–
- 473 444. https://www.ncbi.nlm.nih.gov/books/NBK513574/
- 474 Jonsyn-Ellis, F. E. (2000). Aflatoxins and ochratoxins in urine samples of school children in Mokonde, Southern
- 475 Sierra Leone. Journal of Nutritional and Environmental Medicine, 10(3), 225–231.
 476 https://doi.org/10.1080/13590840050134890
- 477 Karima, H. K., Ridha, G., Zied, A., Chekib, M., Salem, M., & Abderrazek, H. (2010). Estimation of Ochratoxin
- 478 A in human blood of healthy Tunisian population. *Experimental and Toxicologic Pathology*, 62(5), 539–
 479 542. https://doi.org/10.1016/J.ETP.2009.07.005
- 480 Kőszegi, T., & Poór, M. (2016). Ochratoxin A: Molecular Interactions, Mechanisms of Toxicity and Prevention
 481 at the Molecular Level. *Toxins 2016, Vol. 8, Page 111, 8*(4), 111. https://doi.org/10.3390/TOXINS8040111
- 482 Kpoda, D. S., Bandé, M., Ouattara, A. S., Bazié, R. B. S., Compaoré, A. M., Meda, R. N., Meda, D. S., Bakyono,
- 483 R., Kabré, E., Somda, S., Kpoda, H. B. N., Somé, S. A., Sakana, L., Kaboré, F., Ilboudo, B., Konaté, B.,
- 484 Ouangrawa, S., Sié, A., Ouattara, M., ... Hien, H. (2022). Nutritional, Microbiological, and Toxicological
- 485 Quality Assessment of Foods Sold in Urban and Suburban Markets in Burkina Faso.
 486 *Https://Home.Liebertpub.Com/Hs*, 20(4), 298–307. https://doi.org/10.1089/HS.2022.0023
- 487 Kyei, N. N. A., Boakye, D., & Gabrysch, S. (2020). Maternal mycotoxin exposure and adverse pregnancy
 488 outcomes: a systematic review. *Mycotoxin Research*, *36*(2), 243–255. https://doi.org/10.1007/S12550-019489 00384-6
- 490 Lauer, J. M., Natamba, B. K., Ghosh, S., Webb, P., Wang, J. S., & Griffiths, J. K. (2020). Aflatoxin exposure in
- 491 pregnant women of mixed status of human immunodeficiency virus infection and rate of gestational weight
- 492 gain: a Ugandan cohort study. *Tropical Medicine and International Health*, 25(9), 1145–1154.
 493 https://doi.org/10.1111/TMI.13457
- 494 Lee, S. E., Talegawkar, S. A., Merialdi, M., & Caulfield, L. E. (2013). Dietary intakes of women during pregnancy
- in low- and middle-income countries. In *Public Health Nutrition* (Vol. 16, Issue 8, pp. 1340–1353).
- 496 https://doi.org/10.1017/S1368980012004417

- 497 Liu, J., Wu, S., Shen, H., Cui, J., Wang, Y., Xing, L., Wang, J., Yan, X., & Zhang, X. (2015). Ochratoxin A induces
- 498 DNA damage and G2 phase arrest in human esophageal epithelium Het-1A cells in vitro. The Journal of
- 499 Toxicological Sciences, 40(5), 657–665. https://doi.org/10.2131/JTS.40.657
- 500 Lombard, M. J. (2014). Mycotoxin Exposure and Infant and Young Child Growth in Africa: What Do We Know? 501 Annals of Nutrition and Metabolism, 64(Suppl. 2), 42-52. https://doi.org/10.1159/000365126
- 502
- 503 breast milk samples in Tabriz-Iran. Maternal and Child Health Journal, 14(1), 141-145. 504 https://doi.org/10.1007/S10995-008-0439-9

Mahdavi, R., Nikniaz, L., Arefhosseini, S. R., & Vahed Jabbari, M. (2010). Determination of aflatoxin M(1) in

- 505 Marin, S., Ramos, A. J., Cano-Sancho, G., & Sanchis, V. (2013). Mycotoxins: occurrence, toxicology, and 506 exposure assessment. Food and Chemical Toxicology: An International Journal Published for the British 507 Industrial Biological Research Association, 60, 218-237. https://doi.org/10.1016/J.FCT.2013.07.047
- 508 Matumba, L., Namaumbo, S., Ngoma, T., Meleke, N., De Boevre, M., Logrieco, A. F., & De Saeger, S. (2021).
- 509 Five keys to prevention and control of mycotoxins in grains: A proposal. Global Food Security, 30, 100562. 510 https://doi.org/10.1016/J.GFS.2021.100562
- 511 McCormick, S. P., Kato, T., Maragos, C. M., Busman, M., Lattanzio, V. M. T., Galaverna, G., Dall-Asta, C.,
- 512 Crich, D., Price, N. P. J., & Kurtzman, C. P. (2015). Anomericity of T-2 toxin-glucoside: Masked mycotoxin
- 513 Agricultural Food 63(2), 731–738. in cereal crops. Journal of and Chemistry,
- 514 https://doi.org/10.1021/JF504737F/SUPPL FILE/JF504737F SI 001.PDF
- 515 Ngum, N. Q., Babalola, O. O., Ekwomadu, T. I., Nleya, N., & Mulunda, M. (2022). Six Main Contributing Factors
- 516 to High Levels of Mycotoxin Contamination in African Foods. Toxins 2022, Vol. 14, Page 318, 14(5), 318.
- 517 https://doi.org/10.3390/TOXINS14050318
- 518 Nielsen, J. K. S., Vikström, A. C., Turner, P., & Knudsen, L. E. (2011). Deoxynivalenol transport across the human 519 49(9), placental barrier. Food and Chemical Toxicology, 2046-2052. 520 https://doi.org/10.1016/J.FCT.2011.05.016
- 521 Ota, E., Ganchimeg, T., Morisaki, N., Vogel, J. P., Pileggi, C., Ortiz-Panozo, E., Souza, J. P., & Mori, R. (2014).
- 522 Risk factors and adverse perinatal outcomes among term and preterm infants born small-for-gestational-age:
- 523 secondary analyses of the WHO Multi-Country Survey on Maternal and Newborn Health. PloS One, 9(8).
- 524 https://doi.org/10.1371/JOURNAL.PONE.0105155

- 525 Pfohl-Leszkowicz, A., & Manderville, R. A. (2007). Ochratoxin A: An overview on toxicity and carcinogenicity 526 & in animals and humans. Molecular Nutrition Food Research. 51(1), 61–99. 527 https://doi.org/10.1002/MNFR.200600137
- 528 Pfohl-Leszkowicz A, Tozlovanu M, Stepanovic J, Stefanovic V, Manderville R, & Castegnaro M. (2006).
- 529 Comparative genotoxicity of ochratoxin A and aristolochic acid in human kidney cells: Interpretation of
- 530 ongoing analyses of food, blood, urine and kidney tissue from Serbia (Vol. 30).
 531 https://plus.cobiss.net/cobiss/sr/sr/bib/1026369973
- 532 Pitt, J. I., Basílico, J. C., Abarca, M. L., & López, C. (2000). Mycotoxins and toxigenic fungi. *Medical Mycology*,
 533 38, 41–46. https://doi.org/10.1080/MMY.38.S1.41.46
- Ringot, D., Chango, A., Schneider, Y. J., & Larondelle, Y. (2006). Toxicokinetics and toxicodynamics of
 ochratoxin A, an update. *Chemico-Biological Interactions*, 159(1), 18–46.
 https://doi.org/10.1016/J.CBI.2005.10.106
- Schwartz, G. G. (2002). Hypothesis: does ochratoxin A cause testicular cancer? *Cancer Causes & Control : CCC*, *13*(1), 91–100. https://doi.org/10.1023/A:1013973715289
- Silva, L. J. G., Macedo, L., Pereira, A. M. P. T., Duarte, S., Lino, C. M., & Pena, A. (2020). Ochratoxin A and
 Portuguese children: Urine biomonitoring, intake estimation and risk assessment. *Food and Chemical Toxicology*, *135*, 110883. https://doi.org/10.1016/J.FCT.2019.110883
- 542 Skaug, M. A., Helland, I., Solvoll, K., Saugstad, O. D., Skaug{, M. A., Helland{, I., Solvoll}, K., & Saugstad{, O.
- 543 D. (2001). Presence of ochratoxin A in human milk in relation to dietary intake. *Food Additives and* 544 *Contaminants*, *18*(4), 321–327. https://doi.org/10.1080/02652030117740
- 545 Somda, M. K., Dabire, Y., Mogmenga, I., Ouattara, A., Nikiema, M., Mihin, H. B., Akakpo, A. Y., Kabore, D.,
- 546 Traore, A. S., Dicko, M. H., Ki-Zerbo, J., & Faso, B. (2023). Assessment of Maize Contamination by
- 547 Aflatoxin in Burkina Faso: A Review of Methods of Control. *Food and Nutrition Sciences*, 14, 135–147.
- 548 https://doi.org/10.4236/fns.2023.142010
- 549 Tan, T., Chen, T., Zhu, W., Gong, L., Yan, Y., Li, Q., Chen, L., Li, Y., Liu, J., Li, Y., Yang, X., Hao, L., Wang,
- 550 H., Yang, N., & Wei, S. (2023). Adverse associations between maternal deoxynivalenol exposure and birth
- outcomes: a prospective cohort study in China. *BMC Medicine*, 21(1), 1–11. https://doi.org/10.1186/S12916 023-03011-5/TABLES/5
- 553 Tesfamariam, K., Argaw, A., Hanley-Cook, G. T., Gebreyesus, S. H., Kolsteren, P., Belachew, T., Van de Velde,
- 554 M., De Saeger, S., De Boevre, M., & Lachat, C. (2022). Multiple mycotoxin exposure during pregnancy and

risks of adverse birth outcomes: a prospective cohort study in rural Ethiopia. *Environment International*,

556 160, 107052. https://doi.org/10.1016/j.envint.2021.107052

557 Tesfamariam, K., De Boevre, M., Kolsteren, P., Belachew, T., Mesfin, A., De Saeger, S., & Lachat, C. (2020).

558Dietary mycotoxins exposure and child growth, immune system, morbidity, and mortality: a systematic559literature review. Critical Reviews in Food Science and Nutrition, 60(19), 3321–3341.

560 https://doi.org/10.1080/10408398.2019.1685455

- Tesfamariam, K., Gebreyesus, S. H., Lachat, C., Hanley-Cook, G. T., Roro, M., Mengistu, Y. G., Endris, B. S.,
- Belachew, T., Kolsteren, P., De Saeger, S., De Boevre, M., & Argaw, A. (2022). Chronic aflatoxin exposure
- 563 during pregnancy is associated with lower fetal growth trajectories: a prospective cohort from the Butajira
- 564 Nutrition, Mental Health, and Pregnancy (BUNMAP) Study in rural Ethiopia. The American Journal of

565 *Clinical Nutrition*, *116*(6), 1634–1641. https://doi.org/10.1093/AJCN/NQAC280

- Thompson, M., Ellison, S. L. R., & Wood, R. (2002). Harmonized guidelines for single-laboratory validation of
 methods of analysis (IUPAC Technical Report). *Pure and Applied Chemistry*, 74(5), 835–855.
 https://doi.org/10.1351/PAC200274050835/MACHINEREADABLECITATION/RIS
- Vanslambrouck, K., De Kok, B., Toe, L. C., De Cock, N., Ouedraogo, M., Dailey-Chwalibóg, T., Hanley-Cook,
 G., Ganaba, R., Lachat, C., Huybregts, L., & Kolsteren, P. (2021). Effect of balanced energy-protein
 supplementation during pregnancy and lactation on birth outcomes and infant growth in rural Burkina Faso:
 study protocol for a randomised controlled trial. *BMJ Open*, *11*(3). https://doi.org/10.1136/BMJOPEN-2020-

573 038393

- Vidal, A., Belova, L., Stove, C., De Boevre, M., & De Saeger, S. (2021). Volumetric Absorptive Microsampling
 as an Alternative Tool for Biomonitoring of Multi-Mycotoxin Exposure in Resource-Limited Areas. *Toxins*, *13*(5). https://doi.org/10.3390/TOXINS13050345
- 577 Vidal, A., Mengelers, M., Yang, S., De Saeger, S., & De Boevre, M. (2018). Mycotoxin Biomarkers of Exposure:
 578 A Comprehensive Review. *Comprehensive Reviews in Food Science and Food Safety*, *17*(5), 1127–1155.
 579 https://doi.org/10.1111/1541-4337.12367
- 580 Villar, J., Ismail, L. C., Victora, C. G., Ohuma, E. O., Bertino, E., Altman, D. G., Lambert, A., Papageorghiou, A.

581 T., Carvalho, M., Jaffer, Y. A., Gravett, M. G., Purwar, M., Frederick, I. O., Noble, A. J., Pang, R., Barros,

- 582 F. C., Chumlea, C., Bhutta, Z. A., & Kennedy, S. H. (2014). International standards for newborn weight,
- 583 length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the

- 584 INTERGROWTH-21st Project. *The Lancet*, 384(9946), 857–868. https://doi.org/10.1016/S0140 585 6736(14)60932-6
- 586 Warth, B., Parich, A., Atehnkeng, J., Bandyopadhyay, R., Schuhmacher, R., Sulyok, M., & Krska, R. (2012).
- 587 Quantitation of Mycotoxins in Food and Feed from Burkina Faso and Mozambique Using a Modern LC-
- 588 MS/MS Multitoxin Method. https://doi.org/10.1021/jf302003n
- 589 Woo, C. S. J., Partanen, H., Myllynen, P., Vähäkangas, K., & El-Nezami, H. (2012). Fate of the teratogenic and
- 590 carcinogenic ochratoxin A in human perfused placenta. *Toxicology Letters*, 208(1), 92–99.
 591 https://doi.org/10.1016/J.TOXLET.2011.10.013
- 592 Yacine Ware, L., Durand, N., Nikiema, P. A., Alter, P., Fontana, A., Montet, D., & Barro, N. (2017). Occurrence
- 593 of mycotoxins in commercial infant formulas locally produced in Ouagadougou (Burkina Faso). Food
- 594 *Control*, 73, 518–523. https://doi.org/10.1016/J.FOODCONT.2016.08.047

595

Table 1. Characteristics of study participants

	All subjects (n	OTA unexposed (n	OTA exposed
Characteristics	= 305)	= 150)	(n = 155)
Study health center catchment area			
Boni	47 (15.4)	25 (16.7)	22 (14.2)
Dohoun	38 (12.5)	12 (8.05)	26 (16.8)
Dougoumato II	51 (16.7)	25 (16.7)	26 (16.8)
Karaba	39 (12.8)	9 (6.04)	30 (19.4)
Kari	66 (21.6)	46 (30.7)	20 (12.9)
Koumbia	64 (21.0)	33 (22.0)	31 (20.0)
Household level			
Wealth index, 0 to 10 points	4.69 ± 1.80	4.80 ± 1.77	4.57 ± 1.82
Household food insecurity ^a	213 (70.1)	104 (69.3)	109 (70.8)
Improved primary water source ^b	181 (59.3)	94 (62.7)	87 (56.1)
Improved sanitation facility ^c	195 (63.9)	87 (58.0)	108 (69.7)
Household size	6.50 ± 4.87	7.04 ± 5.48	5.97 ± 4.14
Maternal factors			
Age, years	24.08 ± 5.61	24.40 ± 6.07	23.76 ± 5.13
Ethnic group			
Bwaba	174 (57.0)	87 (58.0)	87 (56.1)
Mossi	99 (32.5)	46 (30.7)	53 (34.2)
Others	32 (9.90)	17 (11.4)	15 (9.60)
Religion pregnant woman			
Muslim	131 (43.0)	60 (40.0)	71 (45.8)
Protestant	73 (23.9)	38 (25.3)	35 (22.6)
Animist	69 (22.6)	40 (26.7)	29 (18.7)
Catholic	23 (7.50)	8 (5.37)	15 (9.74)
No religion, no animist	9 (3.00)	4 (2.70)	5 (3.20)
Primary education and above	139 (45.6)	69 (46.0)	70 (45.1)
Trimester of pregnancy at enrollment			
First	239 (78.4)	121 (80.7)	118 (76.1)
Second	66 (21.6)	29 (19.3)	37 (23.9)
Parity			
0	79 (25.9)	36 (24.0)	43 (27.7)
1 to 2	116 (38.0)	58 (38.7)	58 (37.4)
≥3	110 (36.1)	56 (37.3)	54 (34.8)
Weight, kg	58.0 ± 9.79	58.5 ± 10.76	57.5 ± 8.75
Height, cm	162 ± 6.04	163 ± 6.05	162 ± 6.03
BMI, kg/m ²	22.0 ± 3.17	22.1 ± 3.54	21.9 ± 2.77
MUAC, mm	261 ± 27.6	261 ± 28.3	261 ± 27.0
Heamoglobine, g/dL	11.6 ± 1.45	11.6 ± 1.38	11.7 ± 1.51
Anemia (Hb < 11 g/dL)	98 (32.1)	49 (32.7)	49 (31.6)
Diet diversity score ^e , 0 to 10 points	4.05 ± 1.29	4.15 ± 1.38	3.96 ± 1.17

The data are presented as frequencies (%) or means \pm standard deviation (SD).

^aEvaluated using the Household Food Insecurity Access Scale developed by FANTA/USAID.

^bImproved water sources included protected wells, boreholes, piped water, or bottled water.

^cImproved sanitation facilities were defined as flush toilets connected to local sewage or septic tank systems, or pit latrines equipped with a slab and/or ventilation.

^dThe height of one woman with a physical disability could not be determined.

^e An average food group diversity score was computed from the list-based recalls collected on different days throughout the entire pregnancy. BMI, body mass index; HB, hemoglobin; MUAC, mid-upper arm circumference; OTA, ochratoxin A.

Mycotoxins	Positive samples: n (%)	Median (range) µg/L
15-acetyldeoxynivalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
3-acetyldeoxynivalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
aflatoxin B1	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
aflatoxin B2	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
aflatoxin G1	7 (2.31)	<lod (<lod,="" 0.22)<="" td=""></lod>
aflatoxin G2	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
aflatoxin M1	2 (0.66)	<lod (<lod,="" 1.61)<="" td=""></lod>
alpha-zearalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
alternariol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
alternariol monomethyl ether	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
beauvericin	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
beta- zearalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
citrinin	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
cyclopiazonic acid	4 (1.32)	<lod (<lod,="" 2.77)<="" td=""></lod>
deepoxy- deoxynivalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
deoxynivalenol -3- glucoside	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
deoxynivalenol	1 (0.33)	<lod (0.00,="" 0.60)<="" td=""></lod>
diacetoxyscirpenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
enniatin A	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
enniatin A1	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
enniatin B	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
enniatin B1	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
fumonisin B1	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
fumonisin B2	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
fumonisin B3	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
fusarenone-X	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
neosolaniol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
nivalenol	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
ochratoxin A	154 (50.83)	0.01 (<lod, 8.21)<="" td=""></lod,>
ochratoxin alpha	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
roquefortine-C	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
sterigmatocystine	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
T-2-toxin	4 (1.32)	<lod (<lod,="" 0.75)<="" td=""></lod>
zearalanone	0.00	<lod (<lod,="" <lod)<="" td=""></lod>
zearalenone	0.00	<lod (<lod,="" <lod)<="" td=""></lod>

LOD, limit of detection

Outcomes	OTA unexposed (n = 146)	OTA exposed (n = 150)	Unadjusted beta (95% CI)	р	Adjusted beta (95% CI)	р
Birthweight, kg	3.00 ± 0.50	3.01 ± 0.42	0.01 (-0.11, 0.12)	0.909	0.15 (-0.09, 0.12)	0.779
Low birthweight (<2.5 kg)	20 (13.7)	20 (13.3)	-0.28 (-8.18, 7.62)	0.944	-0.06 (-7.64, 7.53)	0.988
Small-for-gestational age	32 (21.9)	45 (30.0)	6.94 (-3.27, 17.2)	0.182	6.62 (-3.52, 16.7)	0.200
Gestational age, week	39.8 ± 1.68	39.9 ± 1.39	0.19 (-0.18, 0.56)	0.325	0.19 (-0.18, 0.56)	0.309
Preterm delivery (<37 week)	8 (5.48)	4 (2.61)	-2.68 (-7.25, 1.89)	0.249	-2.53 (-7.22, 2.16)	0.289
Length, cm	48.3 ± 2.40	48.6 ± 1.96	0.25 (-0.25, 0.76)	0.326	0.29 (-0.20, 0.79)	0.243
MUAC, mm	99.6 ± 8.95	100.5 ± 8.60	1.08 (-0.90, 3.07)	0.283	1.02 (-0.84, 2.88)	0.280
Head circumference, cm	33.2 ± 1.66	33.4 ± 1.38	0.26 (-0.09, 0.61)	0.144	0.28 (-0.06, 0.62)	0.102
Ponderal index, gm/cm ³	26.4 ± 2.57	26.1 ± 2.42	-0.28 (-0.85, 0.29)	0.333	-0.28 (-0.83, 0.26)	0.308
Chest circumference, cm	31.7 ± 2.00	31.9 ± 1.64	0.18 (-0.26, 0.62)	0.427	0.20 (-0.21, 0.61)	0.335

Table 3. Maternal ochratoxin A exposure during pregnancy and birth outcomes¹

¹Values are mean \pm SD or frequencies (percentages). Beta coefficients, both unadjusted and adjusted, are computed using linear regression models to analyze continuous outcomes and linear probability models with robust variance estimation for the binary outcomes. Every model was adjusted for the health center catchment areas and the prenatal and postnatal interventions arms, while adjusted models additionally contained maternal age, primiparity, baseline BMI and heamoglobin concentration, and household size, wealth index score, access to improved water and sanitation, and food security status. MUAC, mid-upper arm circumference; OTA, ochratoxin A.

Outcomes	OTA unexposed (n = 136)	OTA exposed (n = 138)	Unadjusted beta (95% CI)	р	Adjusted beta (95% CI)	р
Length-for-age Z-score	-0.54 ± 1.24	-0.55 ± 1.04	0.00 (-0.30, 0.29)	0.978	0.00 (-0.28, 0.28)	>0.999
Weight-for-age Z-score	-0.46 ± 1.14	-0.49 ± 0.97	0.00 (-0.27, 0.27)	0.997	0.02 (-0.24, 0.29)	0.861
Weight-for-length Z-score	$\textbf{-0.06} \pm 1.08$	-0.14 ± 1.03	-0.05 (-0.31, 0.21)	0.702	-0.02 (-0.28, 0.24)	0.891
MUAC, mm	141 ± 11.8	139 ± 12.0	-0.23 (-2.97, 2.50)	0.868	0.00 (-2.71, 2.71)	0.999
Head circumference, cm	421 ± 15.1	418 ± 14.7	-2.65 (-6.33, 1.02)	0.157	-2.82 (-6.46, 0.82)	0.128
Hemoglobin, g/dL	10.2 ± 1.26	10.4 ± 1.25	0.3 (-0.27, 0.33)	0.849	-0.00 (-0.30, 0.30)	0.990
Stunting	15 (11.03)	9 (6.47)	-6.51 (-13.5, 0.51)	0.069	-6.67 (-13.9, 0.51)	0.069
Underweight	10 (7.35)	7 (5.07)	-2.11 (-8.52, 4.30)	0.518	-2.10 (-8.91, 4.71)	0.544
Wasting	4 (2.94)	3 (2.17)	-0.54 (-4.19, 3.11)	0.771	-0.71 (-4.55, 3.13)	0.716
Anemia	96 (72.73)	92 (67.15)	-3.00 (-14.3, 8.32)	0.602	-1.93 (-13.1, 9.24)	0.734

Table 4. Maternal ochratoxin A exposure and infant growth and nutritional status at 6 months of age¹

¹Values are mean \pm SD or frequencies (percentages). Beta coefficients, both unadjusted and adjusted, are computed using linear regression models to analyze continuous outcomes and linear probability models with robust variance estimation for the binary outcomes. Every model was adjusted for the health center catchment areas and the prenatal and postnatal interventions arms, while adjusted models additionally contained maternal age, primiparity, baseline BMI and heamoglobin concentration, and household size, wealth index score, access to improved water and sanitation, and food security status. MUAC, mid-upper arm circumference; OTA, ochratoxin A.





Figure 1. Study flow diagram of the Biospecimen sub-study (BioSpé) of the MISAME-III project.



Figure 2: Infant growth trajectories from birth to 6 months by ochratoxin A unexposed groups (solid lines) and exposed (dashed lines).



b







Figure 3. UPLC-MS/MS chromatograms of (A) OTA standard solution 2 µg/L; (B) OTA-naturally contaminated whole blood microsample (concentration 0.89 µg/L); (C) OTA-free whole blood microsample

Color to be used for figure 3.